In a novel development, a team of engineers and pharmacologists from the Indian Institute of Science (IISc) and Al-Ameen College of Pharmacy has come up with nano particles that can stimulate growth of boneforming cells and deliver the drug used for osteoporosis.
Quoting various studies, the team pointed out that at least nine million bone fractures occur annually due to osteoporosis, a progressive bone disease in which the bone loses both its mass and density .
Current treatment regimes involve restricting further bone damage, but not restoring previous strength.
Zoledronic acid (ZOL) is the commonly used drug.
It has successfully reduced risk of fracture in postmenopausal women.
Its prolonged use can cause several adverse effects like unwanted bone changes.
The team has now come up with a modified ZOL drug, proven effective in treatment of postmenopausal osteoporosis.
These are made of synthetic hydroxyapatite (HA).
HA is naturally present in our bodies: it makes up bone mineral and the matrix of teeth and stimulates bone-forming cells.
Deepak Kumar Khajuria, lead author of the team said: We've designed a new formulation, where the ZOL is first adsorbed on nano particles of hydroxyapatite and carried to osteoporotic bone by intravenous injection.
The team has been able to demonstrate successfully that this formulation not only prevents further bone loss, but also stimulates bone growth.